12 Month Price Forecast For GUTS
Distance to GUTS Price Forecasts
GUTS Price Momentum
๐ค Considering Fractyl Health (GUTS)?
Join 5,000+ investors getting our exclusive market analysis every Monday & Thursday. Stay ahead of breakout opportunities.
Disclaimer: The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Data last updated: February 8, 2025 3:36 AM UTC
GUTS Analyst Ratings & Price Targets
Based on our analysis of 2 Wall Street analysts, GUTS has a consensus that is bullish. The median price target is $8.00, with forecasts ranging from $6.00 to $10.00. Currently, there are 3 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
With GUTS currently trading at $1.51, the median price forecast suggests a 429.8% upside. The most optimistic forecast comes from Michael Ulz at Morgan Stanley, projecting a 562.3% upside, while at provides the most conservative target, suggesting a 297.4% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
GUTS Analyst Consensus
GUTS Price Target Range
Latest GUTS Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for GUTS.
Date | Firm | Analyst | Rating | Change | Price Target |
---|---|---|---|---|---|
Feb 3, 2025 | Morgan Stanley | Michael Ulz | Overweight | Maintains | $10.00 |
Feb 28, 2024 | Evercore ISI Group | Umer Raffat | Outperform | Initiates | $0.00 |
Feb 27, 2024 | Morgan Stanley | Michael Ulz | Overweight | Initiates | $18.00 |
Stocks Similar to Fractyl Health, Inc. Common Stock
The following stocks are similar to Fractyl Health based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.

Fractyl Health, Inc. Common Stock (GUTS) Financial Data
Fractyl Health, Inc. Common Stock has a market capitalization of $77.44M with a P/E ratio of -0.8x. The company generates $97,000 in trailing twelve-month revenue with a 35.8% profit margin.
Revenue growth is -61.1% quarter-over-quarter, while maintaining an operating margin of -169,957.1% and return on equity of -286.2%.
Valuation Metrics
Growth & Margins
Financial Health
๐ฅ Want More High-Potential Stock Ideas?
Join 5,000+ investors getting our research on stocks with massive upside potential.

Fractyl Health, Inc. Common Stock (GUTS) Company Overview
About Fractyl Health, Inc. Common Stock
Develops therapies for type 2 diabetes and obesity.
Fractyl Health, Inc. generates revenue by developing innovative therapeutic solutions aimed at treating type 2 diabetes and obesity. Their primary products include the Revita DMR System, an outpatient therapy that addresses duodenal dysfunction, and the Rejuva gene therapy platform, which aims for long-term remission of these metabolic conditions.
Founded in 2010 and headquartered in Burlington, Massachusetts, Fractyl Health, Inc. has evolved from Fractyl Laboratories Inc. and continues to focus on addressing the rising prevalence of metabolic diseases through advanced medical technologies.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
122
CEO
Dr. Harith Rajagopalan M.D., Ph.D.
Country
United States
IPO Year
N/A
Website
fractyl.comFractyl Health, Inc. Common Stock (GUTS) Latest News & Analysis
Revita focuses on weight maintenance after GLP-1 withdrawal due to demand, with midpoint data expected in Q2 2025 and full enrollment in the REMAIN-1 study by summer 2025.
Revita's focus on weight maintenance post-GLP-1 withdrawal aligns with market demand, potentially enhancing its competitiveness. Midpoint data in 2025 could impact stock valuation and investor sentiment.
Fractyl Health's RJVA-001 successfully targets the pancreas in large animal models, showing effective GLP-1 expression and safety. First-in-human studies are set for 2025.
Successful preclinical results for RJVA-001 indicate potential for innovative diabetes treatment. Upcoming human studies could drive stock value and market interest in Fractyl Health.
Fractyl Health, Inc. (Nasdaq: GUTS) will present new preclinical data from its Rejuva platform at the WCIRDC from December 12-14, 2024, focusing on obesity and Type 2 Diabetes treatments.
Fractyl Health's presentation of new preclinical data could signal advancements in obesity and diabetes treatments, potentially impacting stock performance and investor sentiment in the healthcare sector.
Fractyl Health, Inc. (Nasdaq: GUTS) will have CEO Harith Rajagopalan present at two investor conferences, focusing on obesity and Type 2 Diabetes treatments.
Fractyl Health's CEO presenting at investor conferences signals potential growth opportunities and increased visibility for the company, which may attract investor interest and affect stock performance.
Fractyl Health, Inc. (NASDAQ:GUTS) will hold its Q3 2024 earnings conference call on November 12, 2024, at 4:30 PM ET, featuring key executives and analysts from major financial institutions.
Fractyl Health's Q3 earnings call may reveal financial performance and strategic updates, impacting stock valuation and investor sentiment in the healthcare sector.
Fractyl Health Reports Third Quarter 2024 Financial Results and Provides Business Updates
2 months agoFractyl Health, Inc. (Nasdaq: GUTS) reported rapid enrollment in its REMAIN-1 study, with mid-point data expected in Q2 2025. Topline data from REVITALIZE-1 is anticipated in mid-2025.
Rapid enrollment in pivotal studies and upcoming data releases signal potential advancements in obesity and T2D treatments, which could impact Fractyl Healthโs stock performance and market position.
Frequently Asked Questions About GUTS Stock
What is Fractyl Health, Inc. Common Stock's (GUTS) stock forecast for 2025?
Based on our analysis of 2 Wall Street analysts, Fractyl Health, Inc. Common Stock (GUTS) has a median price target of $8.00. The highest price target is $10.00 and the lowest is $6.00.
Is GUTS stock a good investment in 2025?
According to current analyst ratings, GUTS has 3 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $1.51. Always conduct your own research and consider your investment goals before making investment decisions.
What is the price prediction for GUTS stock?
Wall Street analysts predict GUTS stock could reach $8.00 in the next 12 months. This represents a 429.8% increase from the current price of $1.51. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Fractyl Health, Inc. Common Stock's business model?
Fractyl Health, Inc. generates revenue by developing innovative therapeutic solutions aimed at treating type 2 diabetes and obesity. Their primary products include the Revita DMR System, an outpatient therapy that addresses duodenal dysfunction, and the Rejuva gene therapy platform, which aims for long-term remission of these metabolic conditions.
What is the highest forecasted price for GUTS Fractyl Health, Inc. Common Stock?
The highest price target for GUTS is $10.00 from Michael Ulz at Morgan Stanley, which represents a 562.3% increase from the current price of $1.51.
What is the lowest forecasted price for GUTS Fractyl Health, Inc. Common Stock?
The lowest price target for GUTS is $6.00 from at , which represents a 297.4% increase from the current price of $1.51.
What is the overall GUTS consensus from analysts for Fractyl Health, Inc. Common Stock?
The overall analyst consensus for GUTS is bullish. Out of 2 Wall Street analysts, 3 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $8.00.
How accurate are GUTS stock price projections?
Stock price projections, including those for Fractyl Health, Inc. Common Stock, are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.